Cargando…
Efficacy of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia Is Mutation-Independent but Reduced by Calcium Overload
BACKGROUND: The dual Na(+) and cardiac Ca(2+)-release channel inhibitor, Flecainide (FLEC) is effective in patients with catecholaminergic polymorphic ventricular tachycardia (CPVT), a disease caused by mutations in cardiac Ca(2+)-release channels (RyR2), calsequestrin (Casq2), or calmodulin. FLEC s...
Autores principales: | Hwang, Hyun Seok, Baldo, Marcelo P., Rodriguez, Jose Pindado, Faggioni, Michela, Knollmann, Bjorn C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6701460/ https://www.ncbi.nlm.nih.gov/pubmed/31456692 http://dx.doi.org/10.3389/fphys.2019.00992 |
Ejemplares similares
-
The Antiarrhythmic Mechanisms of Flecainide in Catecholaminergic Polymorphic Ventricular Tachycardia
por: Li, Yukun, et al.
Publicado: (2022) -
Insights on the mechanism of flecainide in catecholaminergic polymorphic ventricular tachycardia
por: Davidson, Ross, et al.
Publicado: (2023) -
Questioning flecainide's mechanism of action in the treatment of catecholaminergic polymorphic ventricular tachycardia
por: Williams, Alan J., et al.
Publicado: (2016) -
Antiarrhythmic Effects of Carvedilol and Flecainide in Cardiomyocytes Derived from Catecholaminergic Polymorphic Ventricular Tachycardia Patients
por: Pölönen, R. P., et al.
Publicado: (2018) -
Safety and efficacy of flecainide for patients with catecholaminergic polymorphic ventricular tachycardia: A systematic review and meta-analysis
por: Wang, Guangqiang, et al.
Publicado: (2019)